인쇄하기
취소

Astellas’s ‘Vesicare’ filed lawsuit for infringement by CorePharm Bio

Published: 2016-05-10 14:02:35
Updated: 2016-05-10 14:02:35

On the 4th, Astellas Korea(CEO Hae-do Jung) announced it jointly filed a patent infringement prohibition trial against CorePharm Bio with Astellas Korea to the Seoul Central District Court.

The trial is in regards to ‘Vesicare,’ the Astellas’s hypersensitive bladder treatment.

The Japanese Astellas’s substance patent(expiring in July 13, 2017) related to Vesicare is registered in the pharmac...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.